This inventor holds 1 USPTO granted patent. Top assignee: Precision Nanosystems Ulc. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Shyam Madhusudan Garg: Innovator in Transfection Technology
Introduction
Shyam Madhusudan Garg is a notable inventor based in Richmond, CA, who has made significant contributions to the field of biotechnology. His work primarily focuses on developing innovative solutions for transfecting resistant cell types, which is crucial for advancing genetic research and therapeutic applications.
Latest Patents
Shyam holds a patent for "Compositions for transfecting resistant cell types." This patent describes a transfection reagent composition that includes 30-60 MOL. % of a cationic lipid, or a pharmaceutical acceptable salt thereof; 10-60 MOL % of a structural lipid; 10-20 MOL % of a triglyceride; and 0.1 to about 10 MOL. % of a stabilizing agent. The transfection agent is particularly effective in transfecting cells, especially neurons, with siRNA, mRNA, and plasmid nucleic acid, while maintaining the viability of the cells and the activity of the delivered nucleic acid.
Career Highlights
Shyam Madhusudan Garg is currently associated with Precision Nanosystems Inc., where he continues to push the boundaries of transfection technology. His innovative approach has garnered attention in the scientific community, contributing to advancements in gene delivery systems.
Collaborations
Shyam has collaborated with talented individuals such as Anitha Thomas and Rebecca Anne Grace De Souza, enhancing the research and development efforts at Precision Nanosystems Inc. Their combined expertise fosters a dynamic environment for innovation.
Conclusion
Shyam Madhusudan Garg's contributions to transfection technology exemplify the impact of innovative thinking in biotechnology. His work not only advances scientific understanding but also paves the way for future therapeutic developments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile